Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT ®/AYVAKYT ® (avapritinib) May 31, 2024 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Back: All Posts Next:Caesars Entertainment director buys $319,600 in stock